Monopar Therapeutics (MNPR) Projected to Post Earnings on Thursday

Monopar Therapeutics (NASDAQ:MNPR) will likely be announcing its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect Monopar Therapeutics to post earnings of ($0.8231) per share for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Tuesday, November 17, 2026 at 12:30 PM ET.

Monopar Therapeutics (NASDAQ:MNPR) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.02. On average, analysts expect Monopar Therapeutics to post ($2.98) EPS for the current fiscal year and ($4.29) EPS for the next fiscal year.

Monopar Therapeutics Price Performance

MNPR stock opened at $71.78 on Wednesday. The firm has a fifty day moving average price of $85.31 and a 200 day moving average price of $77.41. Monopar Therapeutics has a fifty-two week low of $50.07 and a fifty-two week high of $124.82.

Insider Buying and Selling

In related news, Director Kim R. Tsuchimoto sold 2,891 shares of Monopar Therapeutics stock in a transaction dated Wednesday, November 4th. The shares were sold at an average price of $71.26, for a total transaction of $206,012.66. Following the completion of the transaction, the director directly owned 1,199 shares of the company’s stock, valued at approximately $85,440.74. The trade was a 70.68% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Christopher M. Starr sold 8,400 shares of the company’s stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $78.50, for a total transaction of $659,400.00. Following the transaction, the director owned 5,173 shares in the company, valued at $406,080.50. The trade was a 61.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 51,920 shares of company stock valued at $4,527,913 in the last three months. Corporate insiders own 9.70% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. Cantor Fitzgerald downgraded shares of Monopar Therapeutics from an “overweight” rating to a “neutral” rating and boosted their target price for the stock from $109.00 to $119.00 in a report on Thursday, August 13th. Zacks Research downgraded shares of Monopar Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 13th. UBS Group set a $125.00 price target on shares of Monopar Therapeutics in a report on Thursday, July 23rd. Barclays reiterated an “overweight” rating and issued a $145.00 price target (up from $128.00) on shares of Monopar Therapeutics in a research report on Friday, September 11th. Finally, BTIG Research boosted their price objective on Monopar Therapeutics from $117.00 to $133.00 and gave the stock a “buy” rating in a research note on Wednesday, August 12th. Six equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $122.78.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. Its pipeline includes radiopharmaceutical candidates designed to target the urokinase plasminogen activator receptor (uPAR), a protein found at elevated levels in some cancers. The company is developing MNPR-101-Zr as an imaging agent to identify uPAR-expressing tumors and MNPR-101-Lu as a potential targeted radiation therapy. These candidates are investigational and are not approved for commercial use.